Sowa Elle M, Fellers Jonathan C, Raisinghani Rachna S, Santa Cruz Maria R, Hidalgo Priscilla C, Lee Meredith S, Martinez Lady A, Keller Adrienne E, Clayton Anita H
Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville (Drs Sowa, Santa Cruz, Hidalgo, Lee, and Clayton); Department of Addiction Psychiatry, Oregon Health and Science University, Portland (Dr Fellers); Psychosomatic Medicine, Virginia Commonwealth University Health System, West Hospital, Richmond (Dr Raisinghani); Child Psychiatry, University of Connecticut, West Hartford (Dr Martinez); and Public Health Sciences, The National Social Norms Institute at the University of Virginia, Charlottesville (Dr Keller).
Prim Care Companion CNS Disord. 2014;16(1). doi: 10.4088/PCC.13m01566. Epub 2014 Jan 2.
To investigate the value of a prescription monitoring program in identifying prescription drug misuse among patients presenting to a resident physician outpatient psychiatry clinic at an academic medical center.
Participants were 314 new patients aged 18 years or older presenting to the clinic from October 2011 to June 2012. Resident physicians completed a data collection form for each participant using information from the patient interview and from the prescription monitoring program report. Prescription drug misuse was defined as having any 1 of the following 5 criteria in the prescription monitoring program report: (1) filled prescriptions for 2 or more controlled substances, (2) obtained prescriptions from 2 or more providers, (3) obtained early refills, (4) used 3 or more pharmacies, and (5) the prescription monitoring program report conflicted with the patient's report.
At least 1 indicator of prescription drug misuse was found in 41.7% of patients. Over 69% of the patients that the residents believed were misusing prescription drugs actually met 1 of the criteria for prescription drug misuse. The prescription monitoring program report changed the management only 2.2% of the time. Patients with prior benzodiazepine use (χ(2) 1 = 17.68, P < .001), prior opioid use (χ(2) 1 = 19.98, P < .001), a personality disorder (χ(2) 1 = 7.22, P < .001), and chronic pain (χ(2) 1 = 14.31, P < .001) had a higher percentage of prescription drug misuse compared to patients without these factors.
Using the prescription monitoring program to screen patients with prior benzodiazepine and opioid use, with a personality disorder, and/or with chronic pain may be useful in confirming the suspicion of prescription drug misuse identified at the initial evaluation.
探讨处方监测程序在识别前往某学术医疗中心住院医师门诊精神科就诊患者中处方药物滥用情况的价值。
研究对象为2011年10月至2012年6月期间前往该诊所就诊的314名18岁及以上的新患者。住院医师利用患者访谈信息和处方监测程序报告,为每位参与者填写一份数据收集表。处方药物滥用定义为在处方监测程序报告中符合以下5项标准中的任何1项:(1)开具2种或更多受管制物质的处方;(2)从2名或更多提供者处获得处方;(3)提前获得续方;(4)使用3家或更多药房;(5)处方监测程序报告与患者报告存在冲突。
41.7%的患者至少有1项处方药物滥用指标。住院医师认为滥用处方药物的患者中,超过69%实际上符合处方药物滥用的1项标准。处方监测程序报告仅在2.2%的情况下改变了治疗方案。与没有这些因素的患者相比,既往使用苯二氮䓬类药物(χ(2) 1 = 17.68,P < .001)、既往使用阿片类药物(χ(2) 1 = 19.98,P < .001)、患有精神障碍(χ(2) 1 = 7.22,P < .001)和慢性疼痛(χ(2) 1 = 14.31,P < .001)的患者处方药物滥用的比例更高。
使用处方监测程序筛查既往使用苯二氮䓬类药物和阿片类药物、患有精神障碍和/或慢性疼痛的患者,可能有助于确认在初始评估中发现的处方药物滥用怀疑。